[A19-08] Brigatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V
Last updated 15.04.2019
Project no.:
A19-08
Commission:
Commission awarded on 15.01.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib
Result of dossier assessment:
Added benefit not proven due to lack of suitable study data
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-42 | Brigatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |